Ownership
Private
Employees
~50
Stage
Preclinical
Modalities
Small molecule

Treventis General Information

Entered partnership with Takeda for tau-targeting small molecules in Alzheimer's Disease. Platform technology focuses on protein misfolding drug design.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Treventis's pipeline data

Book a demo

Key Partnerships

Takeda, U.S. Department of Defense

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Treventis Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Treventis's complete valuation and funding history, request access »